医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

iMediSync Leads Global Remote Healthcare Market With Its AI-Based Brain Scanning Device iSyncWave

2022年05月13日 PM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

iMediSync announced it participated in Kotra’s “Innovative Global Startups Showcase.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220513005123/en/

As the COVID-19 pandemic has triggered a mental health crisis such as ‘Corona Blue’ around the globe, mental health has become an important issue. Early diagnosis is critical for discovering mental illnesses such as Alzheimer’s Dementia or clinical depression for better prognosis and as a cost-cutting measure.

Aligned with this, iSyncWave, an innovative AI-based brain-scanning device, gained global media attention during the event. iSyncWave is the world’s first integrated wireless EEG measurement and Neurotherapy convergence solution and is a remote-care mental health platform device. The device is a 100 percent dry-type headset equipped with the age/gender matching normative database with 1,300+ healthy brainwaves covering almost all ages. It offers a high-quality EEG/HRV screening and AI automatic predictive analysis of potential MCI conditions in just 10-minute.

This system could dramatically reduce time and resources. Also, the device is equipped with PBM (Photobiomodulation) LED therapy to suppress brain cells from dying, which provides personalized therapy protocols that target neuro-related diseases.

Meanwhile, after successfully demonstrating iSyncWave at CES 2022, iMediSync has the attention of media and visitors around the world and is receiving numerous collaboration and co-research offers.

iSyncWave has also won the 2022 Red Dot Design Award for its innovative and user-friendly design, and it is highly spoken of meeting the convenience needs of clients along with satisfying technology.

iMediSync solutions have been used by more than 60 hospitals and clinics within South Korea. Being recognized for its technological prowess, iMediSync was selected for Inspira, Israel’s biotechnology investment and development program. iMediSync is actively participating in various studies including joint Research on Promotion of Brain Development in Children and Adolescents through Exercise with Professor John Ratey of the Department of Neuropsychiatry at Harvard Medical School. They are also considering becoming involved in the pharmaceutical industry and developing business relations with various insurance companies and governments in the near future.

iMediSync CEO Seung-Wan Kang stated, “We will provide life-changing mental healthcare experiences by introducing neuro-mental illness biomarkers and the patented Electroencephalogram (EEG)/Heart Rate Variability (HRV) technology. iMediSync will leap forward as a trend leader in the field of telemedicine, and AI medicine and digital therapy will take place in a post-Covid-19 era as an optimized personal mental healthcare service provider.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005123/en/

CONTACT

iMediSync

Seung Eon Jeong (Oversea Business Team)

overseasales@imedisync.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June
  • IntelliCentrics Seeks Strategic Alliance With Taiwanese Health Insurance Providers to Serve Millions of Taiwanese Patients Ensuring They Have Remote Access to Trusted, High Quality Healthcare.
  • 中智全球寻求与台湾医疗保险公司结成战略联盟,为数百万台湾患者提供服务,确保他们能够远程获得可靠及优质的医疗保健服务。
  • Sermo调查显示,今年ASCO的与会肿瘤学家对新的肺癌和乳腺癌研究最感兴趣
  • 訂正・差し替え SCAI 2022 Scientific Meeting で心原性ショックの予後改善に向けた Impella の研究と進歩を大きく紹介